BioSpace News Archive

CinCor Pharma, Inc. announced the pricing of its initial public offering of 12,100,000 shares of common stock at a price to the public of $16.00 per share.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), wishes to clarify certain disclosures in its press release titled “Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19,” issued on December 29, 2021 that provided an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employee’s acceptance of employment with the company.

BD, a leading global medical technology company, announced that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendees in light of the current and ongoing COVID-19 pandemic, the format of its 2022 Annual Meeting of Shareholders has been changed to a virtual-only meeting.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.

Cellusion Inc. announced it has completed a 1.1 billion yen fundraising round led by existing investors DBJ Capital, Keio Innovation Initiative, and SMBC Venture Capital and new investors Gemseki, Toho Holding, Toyo Seikan Group Holdings and University of Tokyo Edge Capital Partners.

Amylyx Pharmaceuticals, Inc. announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock pursuant to registration statements on Form S-1 filed with the U.S. Securities and Exchange Commission at an initial public offering price of $19.00 per share.

Rakovina Therapeutics Inc. is pleased to announce that it is presenting virtually at the Biotech Showcase™ 2022 conference, which is being held virtually January 10-12 and January 17-19, 2022.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022.

REALM IDx, Inc., a leader in integrated diagnostics, announced the company will participate in the upcoming 40th Annual J.P. Morgan Health Care Conference.